PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating ...

Cognition Therapeutics (NASDAQ:CGTX) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 'SHINE' study. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. More Monday Stock Market News What's Next for CGTX Stock Thi ...

- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration - - Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings - "The SHINE trial showed that after 182 days of treatment, CT1812 demonstrated evidence of clinical improvements ...

PURCHASE, N.Y., July 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today reported that participants in the proof-of-concept Phase 2 'SHINE' study (NCT03507790) who were treated with CT1812 for six months showed a consistent trend in cognitive improvement compared to placebo across all cognitive measures including ADAS-Cog 11, ADAS-Cog 13, cognitive composite and MMSE. ...

The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial which enrolled 153 patients with mild-to-moderate Alzheimer's disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant ...

Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday. AAIC Presentation details 1. Abstract #95147: CSF Phosphoproteomics Biomarker An ...

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, ...

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, ...

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: "Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease." This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. This conversation features a discussion of newly ...

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: "Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease." This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. Our podcast series does not constitute the practi ...